BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26841802)

  • 1. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
    Parikh SA; Strati P; Tsang M; West CP; Shanafelt TD
    Blood; 2016 Apr; 127(14):1752-60. PubMed ID: 26841802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
    Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
    Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.
    Vetro C; Haferlach T; Jeromin S; Stengel A; Zenger M; Nadarajah N; Baer C; Weissmann S; Kern W; Meggendorfer M; Haferlach C
    Br J Haematol; 2018 Oct; 183(1):47-59. PubMed ID: 30022491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.
    Best OG; Gardiner AC; Davis ZA; Tracy I; Ibbotson RE; Majid A; Dyer MJ; Oscier DG
    Leukemia; 2009 Jan; 23(1):212-4. PubMed ID: 18818700
    [No Abstract]   [Full Text] [Related]  

  • 9. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.
    Osman A; Gocke CD; Gladstone DE
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):97-99. PubMed ID: 28041846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and risk stratification in chronic lymphocytic leukemia.
    Parikh SA; Shanafelt TD
    Semin Oncol; 2016 Apr; 43(2):233-40. PubMed ID: 27040701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
    Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
    Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
    Stanganelli C; Travella A; Bezares R; Slavutsky I
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.
    Raponi S; Del Giudice I; Marinelli M; Wang J; Cafforio L; Ilari C; Piciocchi A; Messina M; Bonina S; Tavolaro S; Bordyuh M; Mariglia P; Peragine N; Mauro FR; Chiaretti S; Molica S; Gentile M; Visentin A; Trentin L; Rigolin GM; Cuneo A; Diop F; Rossi D; Gaidano G; Guarini A; Rabadan R; Foà R
    Ann Oncol; 2018 Apr; 29(4):966-972. PubMed ID: 29365086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
    MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
    Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.